Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - The Lancet, 2019 - thelancet.com
Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - Lancet, 2019 - kups.ub.uni-koeln.de
Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
[引用][C] Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - The Lancet, 2019 - cir.nii.ac.jp
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab
in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised …
in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised …
[引用][C] Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - Lancet, 2019 - oparu.uni-ulm.de
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in
patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised …
patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert… - Lancet (London …, 2019 - europepmc.org
Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - …, 2019 - ub01.uni-tuebingen.de
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab
in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised …
in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - THE LANCET, 2019 - iris.unimore.it
Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
GL Alliance, FLYER Trial Investigators - The Lancet, 2019 - cris.bgu.ac.il
Background: Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - 2019 - mediatum.ub.tum.de
Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …
[引用][C] Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable …
V Poeschel, G Held, M Ziepert, M Witzens-Harig… - 2019 - publications.goettingen-research …